Preview

Systemic Hypertension

Advanced search

Evaluating of the effectiveness and safety of the reproduced selective β1-blocker without intrinsic sympathomimetic activity Bidop® in patients with hypertrophic cardiomyopathy

Abstract

The article assesses the effectiveness of therapy generics Bidop® production of Gedeon Richter (Hungary), designated to improve diastolic function, and treatment of heart failureof patients with hypertrophic cardiomyopathy with predominant hypertrophy of the interventricular septum and symmetrical concentric shape in the absence of obstruction of outflow tract of the left ventricle (LV). The effect of the presence of zones of intramyocardial fibrosis hypertrophied LV departments identified through MRI delayed contrast, to the process of active relaxation.

About the Authors

L. I. Feiskhanova
Kazan State Medical University of the Ministry of Health of the Russian Federation
Russian Federation


A. A. Malov
Kazan State Medical University of the Ministry of Health of the Russian Federation
Russian Federation


References

1. Maron B.J, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathyrelateddeath: Revisitedinalargenon - referral - based patient population. Circulation 2000; 102: 858-64.

2. Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. Гипертрофическая кардиомиопатия. Руководство для врачей. М.: ГЭОТАР-Медиа, 2011.

3. Strauer B.E. Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure. Am J Cardiol 1990; 65: 34G-41G.

4. Davies M.J, Mc Kenna W.J. Hypertrophic cardiomyopathy: Pathology and pathogenesis. Histopathology 1995; 26: 493-500.

5. Elliott P.M, Mc Kenna W.J. Hypertrophic cardiomyopathy. In: Crawford M.H, Di Marco J.P. Eds. Cardiology. London: Mosby, 2001; 5 (12): 1-12.

6. Krayenbuehl H.P, Hess O.M, Schneider J et al. Physiologic or pathologic hypertrophy. Eur Heart J 1983; 4 (Suppl. A): 29-34.

7. Gilbert B.W, Pollick C, Adelman A.G et al. Hypertrophic cardiomyopathy: Subclassification by M-mode echocardiography. Am J Cardiol 1980; 45: 861-71.

8. Bache R.J, Vrobel T.R. Effects of exercise on blood flow in the hypertrophied heart. Am J Cardiol 1979; 44 (6): 1029-33.

9. Elliott P.M, Anastasakis A, Borger M.A et al. Клинические рекомендации ESC по диагностике и лечению гипертрофической кардиомиопатии - 2014. Рос. кардиол. журн. 2015; 5 (121): 7-57.

10. Derereux R.B, Alonso D.R, Lutas E.M et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.

11. Lery D, Garrison R.J, Sarage D.D et al. Prognostic implications of echocardiographycally determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322.


Review

For citations:


Feiskhanova L.I., Malov A.A. Evaluating of the effectiveness and safety of the reproduced selective β1-blocker without intrinsic sympathomimetic activity Bidop® in patients with hypertrophic cardiomyopathy. Systemic Hypertension. 2016;13(2):88-90. (In Russ.)

Views: 103


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)